Project 4: Neoadjuvant Clinical Trial with Pembrolizumab for Locally Advanaced Squamous Cell Carcinoma (SCC)
$381,600P50FY2024CANIH
University Of Pittsburgh At Pittsburgh, Pittsburgh PA
Investigators
Linked publications & trials
Paper 39537211Paper 39486411Paper 39461879Paper 39384819Paper 39121849Paper 39121848Paper 39039662Paper 38949179Paper 38832925Paper 38682653Paper 38655867Paper 38517470Paper 38409643Paper 38372597Paper 38236069Paper 38233089Paper 38036289Paper 37870487Paper 37857525Paper 37713508Paper 37645831Paper 37534980Paper 37410978Paper 37399356Paper 37399019Paper 37378689Paper 37348864Paper 37097465Paper 37028428Paper 36869645Paper 36750253Paper 36656164Paper 36629350Paper 36534010Paper 36383142Paper 36323258Paper 36106401Paper 36103258Paper 35853825Paper 35579997Paper 35468949Paper 35319783Paper 35013003
Abstract
This is a phase II single-arm neoadjuvant pembrolizumab trial in patients with PD-1 naïve resectable locally advanced SCC.
View original record on NIH RePORTER →